Various models have been developed, including the Great score by Vos et al. [20] that incorporates age, fT4, thyrotropin binding inhibitory immunoglobulin (TBII), goiter size and its extended version, the Great + score that includes HLA polymorphisms and PTPN22. In addition, Masiello et al. [22] designed a clinical activity score—including factors such as goiter size, fT4, and GO—that provides valuable clinical guidance for predicting GD recurrence. Here, PTPN22 is linked to goiter.